DOI QR코드

DOI QR Code

Intrawound Vancomycin Powder in Primary Total Hip Arthroplasty Increases Rate of Sterile Wound Complications

  • Dial, Brian L. (Department of Orthopaedic Surgery, Duke University Medical Center) ;
  • Lampley, Alexander J. (Department of Orthopaedic Surgery, Duke University Medical Center) ;
  • Green, Cynthia L. (Department of Orthopaedic Surgery, Duke University Medical Center) ;
  • Hallows, Rhett (Department of Orthopaedic Surgery, Duke University Medical Center)
  • Received : 2017.10.20
  • Accepted : 2018.01.15
  • Published : 2018.03.01

Abstract

Purpose: Total hip arthroplasty (THA) is a successful surgery for the treatment of hip osteoarthritis; however, the risk of a post-operative prosthetic joint infection (PJI) remains at 1% to 2%. The purpose of this study was to investigate the safety profile of using vancomycin powder (VP) to reduce infection rates by reviewing acute postoperative complications. Materials and Methods: A retrospective review of 265 consecutive patients undergoing THA was performed. The first 128 patients, the control group, did not receive VP, and the subsequent 137 patients, the VP group, received VP at the time of wound closure. Patient demographic data, medical comorbidities, and perioperative information were compared. Results: The primary outcome was a post-operative surgical complication within 90 days from surgery. The control and VP group's demographic, medical comorbidities and perioperative information data were statistically similar. Deep infection rate in the control group was 5.5%, whereas the deep infection rate in the VP group was 0.7% (P=0.031). Sterile wound complication rate was 4.4% in the VP group, and 0% in the control group (P=0.030). Remaining complications were not statistically different between the groups. Conclusion: VP was associated with an increase rate of sterile wound complications compared to the control group. The rate of PJI was decreased with the use of VP. We do not recommend for or against the use of VP at time of wound closure to prevent PJI, and higher powered studies will need to be performed to demonstrate the efficacy of VP.

Keywords

References

  1. Kapadia BH, Berg RA, Daley JA, Fritz J, Bhave A, Mont MA. Periprosthetic joint infection. Lancet. 2016;387:386-94. https://doi.org/10.1016/S0140-6736(14)61798-0
  2. Garcia-Cimbrelo E, Cruz-Pardos A, Madero R, Ortega-Andreu M. Total hip arthroplasty with use of the cementless Zweymuller Alloclassic system. A ten to thirteen-year follow-up study. J Bone Joint Surg Am. 2003;85-A:296-303.
  3. D'Angelo F, Murena L, Vulcano E, Zatti G, Cherubino P. Seven to twelve year results with Versys ET cementless stem. A retrospective study of 225 cases. Hip Int. 2010;20: 81-6. https://doi.org/10.1177/112070001002000112
  4. Castoldi F, Rossi R, La Russa M, Sibelli P, Rossi P, Ranawat AS. Ten-year survivorship of the Anatomique Benoist Girard I total hip arthroplasty. J Arthroplasty. 2007;22:363-8. https://doi.org/10.1016/j.arth.2006.05.022
  5. Herrera A, Canales V, Anderson J, Garcia-Araujo C, Murcia-Mazon A, Tonino AJ. Seven to 10 years followup of an anatomic hip prosthesis: an international study. Clin Orthop Relat Res. 2004;(423):129-37.
  6. Dale H, Hallan G, Hallan G, Espehaug B, Havelin LI, Engesaeter LB. Increasing risk of revision due to deep infection after hip arthroplasty. Acta Orthop. 2009;80:639-45. https://doi.org/10.3109/17453670903506658
  7. Kurtz SM, Lau E, Schmier J, Ong KL, Zhao K, Parvizi J. Infection burden for hip and knee arthroplasty in the United States. J Arthroplasty. 2008;23:984-91. https://doi.org/10.1016/j.arth.2007.10.017
  8. Zmistowski B, Restrepo C, Hess J, Adibi D, Cangoz S, Parvizi J. Unplanned readmission after total joint arthroplasty: rates, reasons, and risk factors. J Bone Joint Surg Am. 2013;95:1869-76. https://doi.org/10.2106/JBJS.L.00679
  9. Ilchmann T, Zimmerli W, Bolliger L, Graber P, Clauss M. Risk of infection in primary, elective total hip arthroplasty with direct anterior approach or lateral transgluteal approach: a prospective cohort study of 1104 hips. BMC Musculoskelet Disord. 2016;17:471. https://doi.org/10.1186/s12891-016-1332-0
  10. Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty. 2012;27(8 Suppl):61-5.e1. https://doi.org/10.1016/j.arth.2012.02.022
  11. Parvizi J, Heller S, Berend KR, Della Valle CJ, Springer BD. Periprosthetic joint infection: the algorithmic approach and emerging evidence. Instr Course Lect. 2015;64:51-60.
  12. Shahi A, Parvizi J. Prevention of periprosthetic joint infection. Arch Bone Jt Surg. 2015;3:72-81.
  13. AlBuhairan B, Hind D, Hutchinson A. Antibiotic prophylaxis for wound infections in total joint arthroplasty: a systematic review. J Bone Joint Surg Br. 2008;90:915-9. https://doi.org/10.2106/JBJS.G.00637
  14. Hanssen AD, Osmon DR, Patel R. Local antibiotic delivery systems: where are we and where are we going? Clin Orthop Relat Res. 2005;(437):111-4.
  15. Kang DG, Holekamp TF, Wagner SC, Lehman RA Jr. Intrasite vancomycin powder for the prevention of surgical site infection in spine surgery: a systematic literature review. Spine J. 2015;15:762-70. https://doi.org/10.1016/j.spinee.2015.01.030
  16. Edelstein AI, Weiner JA, Cook RW, et al. Intra-articular vancomycin powder eliminates methicillin-resistant S. aureus in a rat model of a contaminated intra-articular implant. J Bone Joint Surg Am. 2017;99:232-8. https://doi.org/10.2106/JBJS.16.00127
  17. Otte JE, Politi JR, Chambers B, Smith CA. Intrawound vancomycin powder reduces early prosthetic joint infections in revision hip and knee arthroplasty. Surg Technol Int. 2017;30:284-9.
  18. Ghobrial GM, Cadotte DW, Williams K Jr, Fehlings MG, Harrop JS. Complications from the use of intrawound vancomycin in lumbar spinal surgery: a systematic review. Neurosurg Focus. 2015;39:E11.
  19. Hansen BJ, Hallows RK, Kelley SS. The Rottinger approach for total hip arthroplasty: technique and review of the literature. Curr Rev Musculoskelet Med. 2011;4:132-8. https://doi.org/10.1007/s12178-011-9093-8
  20. Parvizi J, Gehrke T, Chen AF. Proceedings of the International Consensus on Periprosthetic Joint Infection. Bone Joint J. 2013;95-B:1450-2. https://doi.org/10.1302/0301-620X.95B11.33135
  21. Bakhsheshian J, Dahdaleh NS, Lam SK, Savage JW, Smith ZA. The use of vancomycin powder in modern spine surgery: systematic review and meta-analysis of the clinical evidence. World Neurosurg. 2015;83:816-23. https://doi.org/10.1016/j.wneu.2014.12.033
  22. Qadir R, Ochsner JL, Chimento GF, Meyer MS, Waddell B, Zavatsky JM. Establishing a role for vancomycin powder application for prosthetic joint infection prevention-results of a wear simulation study. J Arthroplasty. 2014;29:1449-56. https://doi.org/10.1016/j.arth.2014.02.012
  23. Everhart JS, Andridge RR, Scharschmidt TJ, Mayerson JL, Glassman AH, Lemeshow S. Development and validation of a preoperative surgical site infection risk score for primary or revision knee and hip arthroplasty. J Bone Joint Surg Am. 2016;98:1522-32. https://doi.org/10.2106/JBJS.15.00988
  24. Jahng KH, Bas MA, Rodriguez JA, Cooper HJ. Risk factors for wound complications after direct anterior approach hip arthroplasty. J Arthroplasty. 2016;31:2583-7. https://doi.org/10.1016/j.arth.2016.04.030
  25. Purcell RL, Parks NL, Gargiulo JM, Hamilton WG. Severely obese patients have a higher risk of infection after direct anterior approach total hip arthroplasty. J Arthroplasty. 2016;31(9 Suppl):162-5.
  26. Vander Salm TJ, Okike ON, Pasque MK, et al. Reduction of sternal infection by application of topical vancomycin. J Thorac Cardiovasc Surg. 1989;98:618-22.
  27. Sweet FA, Roh M, Sliva C. Intrawound application of vancomycin for prophylaxis in instrumented thoracolumbar fusions: efficacy, drug levels, and patient outcomes. Spine (Phila Pa 1976). 2011;36:2084-8. https://doi.org/10.1097/BRS.0b013e3181ff2cb1
  28. O'Neill KR, Smith JG, Abtahi AM, et al. Reduced surgical site infections in patients undergoing posterior spinal stabilization of traumatic injuries using vancomycin powder. Spine J. 2011;11:641-6. https://doi.org/10.1016/j.spinee.2011.04.025
  29. Strom RG, Pacione D, Kalhorn SP, Frempong-Boadu AK. Decreased risk of wound infection after posterior cervical fusion with routine local application of vancomycin powder. Spine (Phila Pa 1976). 2013;38:991-4. https://doi.org/10.1097/BRS.0b013e318285b219
  30. Tubaki VR, Rajasekaran S, Shetty AP. Effects of using intravenous antibiotic only versus local intrawound vancomycin antibiotic powder application in addition to intravenous antibiotics on postoperative infection in spine surgery in 907 patients. Spine (Phila Pa 1976). 2013;38:2149-55. https://doi.org/10.1097/BRS.0000000000000015

Cited by

  1. Intrawound vancomycin in primary hip and knee arthroplasty: a safe and cost-effective means to decrease early periprosthetic joint infection vol.4, pp.4, 2018, https://doi.org/10.1016/j.artd.2018.07.011
  2. What’s New in Musculoskeletal Infection vol.101, pp.14, 2018, https://doi.org/10.2106/jbjs.19.00403
  3. Intrawound vancomycin powder increases post-operative wound complications and does not decrease periprosthetic joint infection in primary total and unicompartmental knee arthroplasties vol.27, pp.7, 2019, https://doi.org/10.1007/s00167-019-05498-z
  4. Intrasite Antibiotic Powder for the Prevention of Surgical Site Infection in Extremity Surgery : A Systematic Review vol.28, pp.1, 2020, https://doi.org/10.5435/jaaos-d-18-00475
  5. Encapsulation of collagen mimetic peptide-tethered vancomycin liposomes in collagen-based scaffolds for infection control in wounds vol.103, pp.None, 2018, https://doi.org/10.1016/j.actbio.2019.12.014
  6. No effect of vancomycin powder to prevent infection in primary total knee arthroplasty: a retrospective review of 976 cases vol.28, pp.9, 2018, https://doi.org/10.1007/s00167-019-05778-8
  7. Antibiotic Stewardship for Total Joint Arthroplasty in 2020 vol.28, pp.18, 2018, https://doi.org/10.5435/jaaos-d-19-00850
  8. Intraarticular vancomycin powder is effective in preventing infections following total hip and knee arthroplasty vol.10, pp.1, 2020, https://doi.org/10.1038/s41598-020-69958-0
  9. Intraoperative Site Vancomycin Powder Application in Infected Diabetic Heel Ulcers With Calcaneal Osteomyelitis vol.42, pp.3, 2021, https://doi.org/10.1177/1071100720962480
  10. The bactericidal effect of vancomycin is not altered by tranexamic acid, adrenalin, dexamethasone, or lidocaine in vitro vol.11, pp.1, 2018, https://doi.org/10.1038/s41598-021-90302-7
  11. Intra-wound vancomycin powder for the eradication of periprosthetic joint infection after debridement and implant exchange: experimental study in a rat model vol.21, pp.1, 2018, https://doi.org/10.1186/s12866-021-02399-5
  12. Vancomycin lavage for the incidence of acute surgical site infection following primary total hip arthroplasty and total knee arthroplasty vol.10, pp.1, 2018, https://doi.org/10.12998/wjcc.v10.i1.71